NASALIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NASALIDE (NASALIDE).
Corticosteroid that reduces inflammation by inhibiting phospholipase A2, decreasing arachidonic acid release, and suppressing prostaglandin and leukotriene synthesis.
| Metabolism | Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism. |
| Excretion | Primarily hepatic metabolism via CYP3A4; metabolites and unchanged drug excreted in feces (approximately 60%) and urine (approximately 40%, with <1% unchanged). |
| Half-life | Terminal elimination half-life: 1-2 hours; clinically, intranasal dosing achieves prolonged local effects with minimal systemic accumulation. |
| Protein binding | High (approximately 80%), primarily bound to albumin. |
| Volume of Distribution | Approximately 2.8 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Intranasal: Approximately 49% systemic absorption relative to intravenous administration; oral bioavailability <1% due to extensive first-pass metabolism. |
| Onset of Action | Intranasal: Symptomatic improvement may occur within 12 hours; full benefit typically seen after several days to 1 week. |
| Duration of Action | Duration of clinical effect: 24 hours after a single intranasal dose; sustained effect with daily use. |
| Molecular Weight | 344.5 |
2 sprays (100 mcg total) per nostril twice daily; maximum 8 sprays (400 mcg) per day in each nostril.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment due to potential corticosteroid effects. |
| Pediatric use | Children 6-14 years: 1 spray (50 mcg) per nostril twice daily; maximum 4 sprays (200 mcg) per day in each nostril. Children ≥14 years: same as adult. |
| Geriatric use | No specific adjustment; use lowest effective dose due to potential increased osteoporosis risk. |
| 1st trimester | Insufficient human data; animal studies show no risk. Avoid unless clearly needed. |
| 2nd trimester | Insufficient human data; animal studies show no risk. Avoid unless clearly needed. |
| 3rd trimester | Insufficient human data; animal studies show no risk. Avoid unless clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for NASALIDE (NASALIDE).
| Placental transfer | Based on molecular weight and low systemic bioavailability, placental transfer is expected to be minimal. No specific studies confirm extent. |
| Breastfeeding | Systemic absorption is minimal; unlikely to pass into breast milk in clinically significant amounts. Use with caution in nursing mothers. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to flunisolide or any component of the formulationUntreated nasal mucosal infection (e.g., herpes simplex, fungal, bacterial)
| Precautions | May cause growth suppression in children with prolonged use, Potential for adrenal insufficiency with systemic absorption, Nasal septum perforation and local irritation reported, Monitor for immunosuppression or infections (e.g., Candida) |
| Food/Dietary | No specific food interactions reported. However, avoid grapefruit and grapefruit juice as they may increase systemic absorption via CYP3A4 inhibition, though topical corticosteroids have minimal systemic bioavailability. |
Loading safety data…
| L3 |
| Teratogenic Risk | FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic at high systemic doses. However, intranasal flunisolide has minimal systemic absorption; therefore, fetal exposure is low. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if potential benefit justifies potential risk to the fetus. First trimester: insufficient data; avoid unless necessary. Second and third trimesters: no specific risks identified; limited data suggest safety. |
| Fetal Monitoring | Monitor maternal nasal symptoms for efficacy. No specific fetal monitoring required due to low systemic absorption. However, if used chronically, monitor maternal adrenal function if high doses are used; consider growth monitoring in newborns if prolonged high-dose exposure. |
| Fertility Effects | No specific studies on human fertility. In animal studies, systemic corticosteroids may impair fertility at high doses. Intranasal flunisolide with low systemic bioavailability is unlikely to affect fertility. |
| Clinical Pearls |
| NASALIDE (flunisolide) is a corticosteroid nasal spray for allergic rhinitis. Titrate to lowest effective dose to minimize systemic absorption. Advise patients to clear nasal passages before use. Monitor for nasal irritation, epistaxis, or rarely, septal perforation. Not for acute symptom relief; onset of action may take several days. |
| Patient Advice | Use regularly for best results; do not expect immediate relief. · Shake bottle gently before each use. · Prime the pump by spraying into the air 5-6 times before first use or if not used for 2 weeks. · Blow nose gently before spraying to clear nasal passages. · Insert nozzle into nostril, aim away from the septum, and spray while breathing in. · Avoid spraying into eyes; if contact occurs, rinse with water. · Rinse nozzle with warm water after each use to prevent clogging. · Do not exceed recommended dosage; overuse can lead to systemic side effects. · Contact doctor if symptoms worsen or persist after 3 weeks. |